Supplementary information - Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a population level in Germany

- 3
- 4 Alex Dulovic (PhD)^{1,#}, Barbora Kessel (PhD)^{2,#}, Manuela Harries (MSc)^{2,#}, Matthias Becker (MSc)¹,
- 5 Julia Ortmann (BSc)², Johanna Griesbaum¹, Jennifer Jüngling¹, Daniel Junker (MSc)¹, Pilar Hernandez
- 6 (PhD)², Daniela Gornyk (MSc)², Stephan Glöckner (PhD)², Vanessa Melhorn (PhD)², Stefanie Castell
- 7 (MD)², Jana-Kristin Heise (MSc)², Yvonne Kemmling (MD)², Torsten Tonn (Prof)³, Kerstin Frank
- 8 (PhD)³, Thomas Illig (Prof)⁴, Norman Klopp (PhD)⁴, Neha Warikoo (PhD)², Angelika Rath², Christina
- 9 Suckel (MSc)², Anne Ulrike Marzian², Nicole Grupe², Philipp D. Kaiser (PhD)¹, Bjoern Traenkle
- 10 (PhD)¹, Ulrich Rothbauer (Prof)^{1,5}, Tobias Kerrinnes (PhD)⁶, Gérard Krause (Prof)^{2,7,8}, Berit Lange
- 11 (MD)^{2,8,§,*}, Nicole Schneiderhan-Marra (PhD)^{1,§,*}, Monika Strengert (PhD)^{2,7,§,*}
- 12
- 13 ¹ NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
- 14 ² Helmholtz Centre for Infection Research, Braunschweig, Germany
- 15 ³ Institute of Transfusion Medicine and Immunohematology, German Red Cross, Plauen, Germany
- 16 ⁴ Hannover Unified Biobank, Hannover Medical School, Hannover, Germany
- 17⁵ Pharmaceutical Biotechnology, University of Tübingen, Germany
- 18 ⁶ Helmholtz Institute for RNA-based Infection Research, Würzburg, Germany
- 19⁷ TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover
- 20 Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany
- ⁸ German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany
- 22
- 23 #, § these authors contributed equally to this work.
- 24 * corresponding authors.
- 25
- 26 Corresponding authors contact details:
- 27 Monika Strengert, Phone number: +49(0)53161813103, Email address: monika.strengert@helmholtz-
- 28 <u>hzi.de</u>, Postal address: Inhoffenstraße 7, 38124 Braunschweig, Germany.
- Berit Lange, Phone number: +49(0)53161813110, Email address: <u>berit.lange@helmholtz-hzi.de</u>, Postal
 address: Inhoffenstraße 7, 38124 Braunschweig, Germany.
- 31 Nicole Schneiderhan-Marra, Phone number: +49(0)712151530815, Email address:
- 32 <u>nicole.schneiderhan@nmi.de</u>, Postal address: Markwiesenstraße 55, 72770 Reutlingen, Germany.
- 33





37 Fig. S1. Flow chart for sample selection from MuSPAD cohort.

Sample selection for our vaccine response study from the entire MuSPAD cohort is displayed in a flow chart.
Samples were selected based on selection criteria outlined in method section to examine impact of vaccination
scheme, length and persistence of antibody response. Samples originated from the following study locations:
Aachen 2 (AA2), Chemnitz 1(CH1), Chemnitz 2 (CH2), Vorpommern-Greifswald 1 (VG1), Osnabrück 2 (OS2),
and Magdeburg 2 (MD2). Number of participants is given per group (n), NA: not available.

43



44

45 Fig. S2. Different VoCs reduce antibody ACE2 binding inhibition comparably between SARS-CoV-2 46 vaccination schemes.

47 ACE2 binding inhibition against the SARS-CoV-2 VoC Alpha (B.1.1.7), Beta (B.1.351), Gamma (P1) and Delta 48 (B.1.617.2) RBDs was assessed by an ACE2-RBD competition assay for homologous mRNA (mRNA-1273 49 (M/M, blue), BNT162b2 (P/P, orange)), heterologous prime-boost (AZD1222-mRNA-1273 (A/M, light blue), 50 AZD1222-BNT162b2 (A/P, light green) or vector-based (AZD1222-AZD1222 (A/A, green), Ad26.CoV2.S (J, grey))vaccination schemes in the mix and match cohort. SARS-CoV-2 RBD WT (Figure 3) is again shown for 51 52 clarity and comparison. Data is shown as box and whisker plots. Boxes represent medians, 25th and 75th 53 percentiles and whiskers show the largest and smallest non-outlier values based on 1.5 IQR calculation. Outlier 54 values are shown in clear circles. The threshold for non-responsive samples (ACE2 binding inhibition less than 55 20%) is shown as dotted line. All samples below this can be considered non-responsive. Number of samples per 56 vaccination scheme are stated below the figure.



Fig. S3. SARS-CoV-2 vaccination boosts humoral response among recovered individuals independent of
 vaccination scheme.

61 Differences in vaccination responses of recovered previously SARS-CoV-2 infected individuals from our mix and 62 match cohort were analysed using MULTICOV-AB. SARS-CoV-2 infection status was based on a previous self-63 reported positive PCR/antigen test or a MULTICOV-AB nucleocapsid IgG normalisation ratio above 1. Samples 64 were split according to vaccination scheme (homologous mRNA (mRNA-1273 (M/M, blue), BNT162b2 (P/P, 65 orange)), heterologous prime-boost (AZD1222-mRNA-1273 (A/M, light blue), AZD1222-BNT162b2 (A/P, light 66 green) or vector-based (AZD1222-AZD1222 (A/A, green), Ad26CoV2.S (J, grey)). Boxes represent medians, 25th 67 and 75th percentiles and whiskers show the largest and smallest non-outlier values based on 1.5 IQR calculation. 68 When less than 5 were available per group, only the median is indicated by a line. Time between sampling and 69 full vaccination is displayed as mean and SD for each group. Number of samples per vaccination scheme are stated 70 below the figure. Results of a formal statistical comparison of recovered-vaccinated and SARS-CoV-2 naïve-71 vaccinated individuals is shown in Table S6. 72

73 Table S1. Comorbidities in study participants (n. a.: not applicable; NA: not available; CVD: cardio	vascular
---	----------

74 disease).

Sample cohort (n)	SARS-CoV-2 infection status (n) *	ΔT post- vaccination (days)	Vaccine (n)	Hyper- tension (n, %)	CVD (n, %)	Diabetes (n, %)	Lung disease (n, %)	Cancer (n, %)	Immuno- suppression (n, %)
Mix and match	+ (70)	7-65	M/M (13)	4 (30.8)	1 (7.69)	2 (15.4)	0 (0)	0 (0)	0 (0)
(1470)			P/P (33)	12 (36.0)	4 (12.0)	3 (9.10)	0 (0)	0 (0)	1 (3.0)
			A/A (33)	7 (58.3)	3 (25.0)	2 (16.67)	1 (8.30)	1 (8.30)	2 (16.7)
			A/M (1)	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
			A/P (6)	3 (50.0)	1 (16.7)	0 (0)	1 (16.7)	0 (0)	0 (0)
			J (5)	2 (40.0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (20.0)
	- (1400)		M/M (272)	84 (30.9)	23 (8.46)	13 (4.78)	17 (6.25)	2 (0.74)	11 (4.04)
			P/P (734, 4 NA)	263 (35.8)	101 (13.8)	64 (8.72)	59 (8.04)	20 (2.72)	37 (5.04)
			A/A (228)	91 (39.9)	25 (11.1)	25 (11.0)	12 (5.26)	2 (0.88)	9 (3.95)
			A/M (24)	12 (50.0)	4 (16.7)	2 (8.34)	0 (0)	1 (4.16)	0 (0)
			A/P (114)	43 (37.7)	16 (14.0)	10 (8.77)	10 (8.77)	4 (3.51)	6 (5.26)
			J (24)	9 (37.50)	2 (8.30)	2 (8.30)	2 (8.30)	1 (4.16)	2 (8.30)
Time points (597)	-	5-12	P/P (107)	50 (46.7)	16 (15.0)	6 (5.61)	3 (2.80)	0 (0)	7 (6.50)
			M/M (40)	13 (32.50)	3 (7.50)	3 (7.50)	1 (2.50)	0 (0)	1 (2.50)
		26-30	P/P (102; 1 NA)	31 (30.4)	15 (14.7)	11 (10.8)	12 (11.8)	0 (0)	0 (0)
			M/M (8)	3 (37.5)	1 (12.5)	0 (0)	0 (0)	0 (0)	0 (0)
		54-58	P/P (92)	37 (40.2)	14 (15.2)	7 (7.61)	0 (0)	2 (2.17)	4 (4.35)
			M/M (22)	2 (9.09)	0 (0)	2 (9.09)	2 (9.09)	0 (0)	1 (4.55)
		94-103	P/P (139)	59 (42.5)	18 (13.0)	12 (8.63)	1 (0.72)	7 (5.04)	0 (0)
			M/M (7)	3 (42.9)	1 (14.3)	1 (14.3)	1 (14.3)	1 (14.3)	0 (0)
		129-146	P/P (38)	19 (50.0)	9 (23.7)	7 (18.4)	4 (10.5)	2 (5.26)	4 (10.5)
			M/M (5)	3 (60.0)	2 (40.0)	1 (20.0)	1 (20.0)	0 (0)	0 (0)
		176-203	P/P (36)	5 (13.9)	2 (5.56)	1 (2.78)	2 (5.56)	0 (0)	3 (8.34)
			M/M (0)	n. a.	n. a.	n. a.	n. a.	n. a.	n. a.
Longi- tudinal (90)	-	1 st sample	P/P (90)	35 (39.8)	15 (17.1)	11 (12.5) 8	4 (4.6)	2 (2.22)	3 (3.41)
(90)		∠ sample		(36.7)	(13.3)	8.89)	(3.33)	(1.11)	(10.0)

- 75 Different vaccines and combinations are abbreviated as follows: M/M (two-dose mRNA-1273), P/P (two-dose
- 76 BNT162b2), A/A (two-dose AZD1222), A/M (first dose AZD1222, second dose mRNA-1273), A/P (first dose
- AZD1222, second dose BNT162b2) and J (one-dose Ad26.CoV2.S). The time points sample cohort contains only
- 78 homologous BNT162b2 and mRNA-1273 samples. The longitudinal sample cohort contains only homologous
- 79 BNT162b2 samples.
- 80 * based on self-reported positive PCR/antigen test result at study centre visit and/or MULTICOV-AB
- 81 nucleocapsid IgG S/CO ratio above 1
- 82

83 Table S2. MULTICOV-AB antigen panel.

Virus	Antigen	Manufacturer	Product number
SARS-CoV-2	Spike Trimer	NMI	-
SARS-CoV-2	RBD B.1 (wild-type)	NMI	-
SARS-CoV-2	Nucleocapsid	Aalto	6404-b
SARS-CoV-2	RBD B.1.1.7 (Alpha)	NMI	
SARS-CoV-2	RBD B.1.351 (Beta)	NMI	
SARS-CoV-2	RBD P.3 (Gamma)	NMI	
SARS-CoV-2	RBD B.1.617.2 (Delta)	NMI	
hCoV-OC43	S1 domain	NMI	-
hCoV-OC43	Nucleocapsid	NMI	-
hCoV-HKU1	S1 domain	NMI	-
hCoV-HKU1	Nucleocapsid	NMI	-
hCoV-NL63	S1 domain	NMI	-
hCoV-NL63	Nucleocapsid	NMI	-
hCoV-229E	S1 domain	NMI	-
hCoV-229E	Nucleocapsid	NMI	-

84 List of antigens included in MULTICOV-AB as well as their manufacturer and, if applicable, their product number.

86 Table S3. ACE2-RBD competition antigen panel.

Virus	Antigen	Manufacturer	Amino acid exchanges in RBD
SARS-CoV-2	RBD B.1 (wild-type)	NMI	-
SARS-CoV-2	RBD B.1.1.7 (Alpha)	NMI	N501Y
SARS-CoV-2	RBD B.1.351 (Beta)	NMI	N501Y, E484K, K417N
SARS-CoV-2	RBD P.1 (Gamma)	NMI	N501Y, E484K, K417T
SARS-CoV-2	RBD B.1.617.2 (Delta)	NMI	T478K, L452R

87 List of antigens included in ACE2-RBD competition assay as well as their manufacturer, and the mutations

88 covered within the RBD.

A. WT ACE2 binding inhibition, logit	ing inhibition, logit P/P, n=734 M/M, n=272 A/P, n=114			A/A, n=228				
scale	Est (sd)	p-value	Est (sd)	p-value	Est (sd)	p-value	Est (sd)	p-value
Intercept	3.50 (0.231)		3.39 (0.330)		3.07 (0.538)		-0.52 (0.496)	
Male	-0.25 (0.103)	0.014	-0.05 (0.149)	0.752	-0.33(0.267)	0.218	0.30(0.152)	0.050
Age (per 1 year)	-0.03 (0.003)	< 0.001	0.00 (0.005)	0.431	-0.01 (0.010)	0.251	0.00(0.008)	0.960
Days post-vaccination (ΔT)								
7-27	Ref.		Ref.		Ref.		Ref.	
28-65	-0.69 (0.104)	< 0.001	-0.97 (0.169)	< 0.001	-0.74 (0.260)	0.005	-0.10(0.188)	0.584
Comorbidities								
Cardiovascular	-0.12(0.158)	0.454	-0.54 (0.309)	0.083	-0.03(0.424)	0.937	0.02 (0.241)	0.943
Hypertension	0.19 (0.119)	0.109	-0.13 (0.180)	0.480	-0.08(0.301)	0.789	0.11(0.161)	0.485
Diabetes	-0.04 (0.185)	0.808	0.58(0.386)	0.136	0.84(0.501)	0.095	-0.15(0.242)	0.547
Lung disease*	-0.03(0.187)	0.853	0.53(0.324)	0.104	-0.87(0.513)	0.091	-0.11(0.349)	0.758
Cancer or Immunosuppression*	-0.26(0.192)	0.176	0.29(0.362)	0.418	0.22(0.508)	0.662	-0.61(0.368)	0.099

89 Table S4. Impact of confounders on ACE2 inhibition response towards SARS-CoV-2 wild-type and VoC RBDs.

B. Alpha ACE2 binding inhibition , logit	P/P, n=734		M/M, n=272	M/M, n=272		A/P, n=114		A/A, n=228	
scale	Est (sd)	p-value	Est (sd)	p-value	Est (sd)	p-value	Est (sd)	p-value	
Intercept	2.50(0.211)		2.64(0.301)		2.26(0.465)		-0.77(0.420)		
Male	-0.22(0.083)	0.008	-0.02(0.130)	0.862	-0.27(0.226)	0.228	0.24(0.126)	0.060	
Age (per 1 year)	-0.02(0.003)	< 0.001	-0.01(0.004)	0.218	-0.01(0.009)	0.270	0.00(0.006)	0.826	
Days post-vaccination (ΔT)									
7-27	Ref.		Ref.		Ref.		Ref.		
28-65	-0.56(0.083)	< 0.001	-0.89(0.147)	< 0.001	-0.58(0.219)	0.008	03(0.155)	0.842	
Comorbidities									
Cardiovascular	-0.10(0.125)	0.434	-0.42(0.266)	0.112	-0.02(0.361)	0.961	0.04(0.202)	0.842	
Hypertension	0.16(0.095)	0.087	-0.10(0.156)	0.524	-0.06(0.255)	0.800	0.05(0.134)	0.715	
Diabetes	-0.03(0.149)	0.828	0.41(0.332)	0.216	0.81(0.425)	0.057	-0.05(0.204)	0.815	
Lung disease*	-0.03(0.149)	0.851	0.40(0.281)	0.156	-0.78(0.433)	0.073	-0.08(0.288)	0.789	
Cancer or Immunosuppression*	-0.15(0.153)	0.343	0.21(0.314)	0.510	0.15(0.428)	0.724	-0.45(0.302)	0.139	

C. Beta ACE2 binding inhibition, logit	P/P, n=734		M/M, n=272	M/M, n=272		A/P, n=114		A/A, n=228	
scale	Est (sd)	p-value	Est (sd)	p-value	Est (sd)	p-value	Est (sd)	p-value	
Intercept	1.27(0.259)		1.55(0.309)		1.12(0.420)		-1.18(0.432)		
Male	-0.19(0.070)	0.006	-0.08(0.105)	0.448	-0.27(0.180)	0.131	0.11(0.116)	0.337	
Age (per 1 year)	-0.02(0.002)	< 0.001	0.00(0.004)	0.170	-0.01(0.007)	0.268	0.00(0.006)	0.584	
Days post-vaccination (ΔT)									
7-27	Ref.		Ref.		Ref.		Ref.		
28-65	-0.44(0.070)	< 0.001	-0.86(0.119)	< 0.001	-0.59(0.175)	0.001	0.07(0.144)	0.645	
Comorbidities									
Cardiovascular	0.00(0.106)	0.971	-0.37(0.216)	0.088	-0.04(0.294)	0.899	0.06(0.181)	0.741	
Hypertension	0.08(0.081)	0.306	-0.12(0.126)	0.323	-0.02(0.205)	0.923	0.01(0.122)	0.940	
Diabetes	0.01(0.124)	0.917	0.24(0.270)	0.380	0.48(0.345)	0.165	0.09(0.180)	0.636	
Lung disease*	-0.08(0.126)	0.520	0.39(0.227)	0.087	-0.54(0.346)	0.117	0.10(0.268)	0.705	
Cancer or Immunosuppression*	-0.19(0.130)	0.155	0.13(0.254)	0.606	0.27(0.340)	0.426	-0.40(0.286)	0.163	

D. Gamma ACE2 binding inhibition,	P/P, n=734		M/M, n=272	M/M, n=272		A/P, n=114		A/A, n=228	
logit scale	Est (sd)	p-value	Est (sd)	p-value	Est (sd)	p-value	Est (sd)	p-value	
Intercept	1.31(0.169)		1.64(0.250)		1.24(0.377)		-1.05(0.313)		
Male	-0.20(0.067)	0.003	-0.06(0.109)	0.612	-0.36(0.183)	0.049	0.13(0.092)	0.165	
Age (per 1 year)	-0.02(0.002)	< 0.001	0.00(0.004)	0.222	-0.01(0.007)	0.183	0.00(0.005)	0.382	
Days post-vaccination (ΔT)		·							
7-27	Ref.		Ref.		Ref.		Ref.		
28-65	-0.46(0.068)	< 0.001	-0.91(0.124)	< 0.001	-0.52(0.177)	0.004	-0.03(0.114)	0.769	
Comorbidities									
Cardiovascular	-0.06(0.101)	0.556	-0.41(0.225)	0.069	-0.05(0.299)	0.862	0.13(0.145)	0.352	
Hypertension	0.14(0.078)	0.063	-0.08(0.132)	0.548	0.04(0.208)	0.862	0.07(0.097)	0.496	
Diabetes	-0.01(0.118)	0.960	0.21(0.281)	0.463	0.53(0.351)	0.134	0.03(0.145)	0.821	
Lung disease*	-0.04(0.121)	0.770	0.27(0.237)	0.252	-0.62(0.351)	0.076	-0.13(0.212)	0.554	
Cancer or Immunosuppression*	-0.17(0.125)	0.178	0.12(0.265)	0.654	0.17(0.344)	0.626	-0.45(0.225)	0.047	

E. Delta ACE2 binding inhibition, logit	P/P, n=734		M/M, n=272		A/P, n=114		A/A, n=228	
scale	Est (sd)	p-value						
Intercept	2.34(0.218)		2.53(0.312)		2.16(0.468)		-1.10(0.430)	
Male	-0.21(0.085)	0.013	-0.03(0.135)	0.830	-0.34(0.226)	0.132	0.20(0.128)	0.128
Age (per 1 year)	-0.02(0.003)	< 0.001	0.00(0.004)	0.349	-0.01(0.009)	0.203	0.00(0.007)	0.698
Days post-vaccination (ΔT)								
7-27	Ref.		Ref.		Ref.		Ref.	
28-65	-0.55(0.086)	< 0.001	-0.99(0.152)	< 0.001	-0.70(0.220)	0.001	0.01(0.159)	0.938
Comorbidities		l						
Cardiovascular	-0.10(0.130)	0.445	-0.52(0.276)	0.058	0.12(0.365)	0.744	0.09(0.203)	0.641
Hypertension	0.15(0.099)	0.125	-0.11(0.162)	0.501	0.01(0.256)	0.957	-0.04(0.136)	0.762
Diabetes	-0.01(0.152)	0.969	0.42(0.345)	0.227	0.68(0.429)	0.116	-0.01(0.204)	0.953
Lung disease*	-0.02(0.155)	0.920	0.39(0.292)	0.182	-0.67(0.434)	0.125	-0.15(0.295)	0.604
Cancer or Immunosuppression*	-0.18(0.159)	0.261	0.17(0.326)	0.603	0.06(0.428)	0.888	-0.50(0.311)	0.111

101 ACE2 binding inhibition towards SARS-CoV-2 wild-type (A) and Alpha (B), Beta (C), Gamma (D), Delta (E) VoC in the mix and match sample cohort was modelled

102 to assess the role of confounders (see methods for model details). Four samples (P/P) had missing information on comorbidities and were excluded from the analysis.

103 Est=estimate, sd=standard deviation. Categories denoted with * were merged in the sensitivity analysis including interaction terms with time post-vaccination due to

104 limited sample sizes (selected results reported in the main text).

105

.

107	Table S5.	Statistical	comparison	of antibody	y titres betw	een vaccination	schemes.
				-	*		

Compar X vs.	ison Y	Full-length Spike trimer p" (p-value)	RBD p" (p-value)	S1 p'' (p-value)	S2 p" (p-value)
J	M/M	0.91 (< 0.001) *	0.93 (<0.001) *	0.96 (<0.001) *	0.86 (< 0.001) *
	P/P	0.89 (<0.001) *	0.90 (<0.001) *	0.92 (<0.001) *	0.79 (< 0.001) *
	A/M	0.89 (<0.001) *	0.91 (<0.001) *	0.97 (<0.001) *	0.93 (<0.001) *
	A/P	0.90 (<0.001) *	0.92 (<0.001) *	0.95 (<0.001) *	0.88 (<0.001) *
	A/A	0.63 (<0.080)	0.74 (<0.001) *	0.86 (<0.001) *	0.81 (<0.001) *
A/A	M/M	0.96 (<0.001) *	0.94 (<0.001) *	0.93 (<0.001) *	0.57 (0.013) *
	P/P	0.91 (<0.001) *	0.87 (<0.001) *	0.83 (<0.001) *	0.39 (<0.001) *
	A/M	0.93 (<0.001) *	0.91 (<0.001) *	0.93 (<0.001) *	0.84 (< 0.001) *
	A/P	0.93 (<0.001) *	0.89 (<0.001) *	0.91 (<0.001) *	0.66 (< 0.001) *
A/P	M/M	0.60 (0.002) *	0.64 (<0.001) *	0.55 (0.114)	0.38 (< 0.001) *
	P/P	0.42 (0.012)	0.49 (0.608)	0.34 (<0.001) *	0.21 (< 0.001) *
	A/M	0.59 (0.204)	0.59 (0.155)	0.69 (0.004) *	0.77 (<0.001) *
A/M	M/M	0.50 (0.982)	0.53 (0.623)	0.33 (0.014) *	0.16 (<0.001) *
	P/P	0.33 (0.014)	0.40 (0.085)	0.18 (<0.001)*	0.09 (<0.001) *
P/P	M/M	0.69 (<0.001) *	0.64 (<0.001) *	0.72 (<0.001) *	0.71 (<0.001) *

108 Estimated probability (p'') that a random individual under one vaccination scheme in the mix and match sample

cohort, has a larger titre than a random individual under another vaccination scheme. Brunner-Munzel was used
 to determine statistical significance with Holm's adjustment for multiple testing. For a comparison of a scheme X

with a scheme Y, a significant p" larger than $\frac{1}{2}$ means that the vaccination-induced titres under Y tend to be

higher and a significant p" inger than $\frac{1}{2}$ means that the vaccination-induced titres under X tend to be higher.

Table S6. Statistical comparison of RBD antibody titres and wild-type ACE2 binding inhibition in recovered vaccinated and SARS-CoV-2 naïve-vaccinated individuals for different vaccination schemes

	M/M	P/P	A/M	A/P	A/A	J
	p" (p-value)	p" (p-value)	p" (p-value)	p" (p-value)	p" (p-value)	p" (p-value)
RBD	0.66	0.79	(only 1	0.79	0.94	0.98
	(0.074)	(<0.001)	convalescent)	(<0.001)	(<0.001)	(<0.001)
AC2 binding inhibition against WT	0.74 (0.016)	0.85 (<0.001)	(only 1 convalescent)	0.84 (0.004)	0.97 (<0.001)	0.98 (<0.001)

116 Estimated probability (p'') that a random recovered-vaccinated individual has a larger titre than a random SARS-

117 CoV-2 naïve vaccinated individual under the respective vaccination scheme. Statistical analysis was determined

by Brunner-Munzel. A significant p'' larger than ½ means that the vaccination-induced titres tend to be higher in recovered-vaccinated individuals.

120

121